Clinical Trial Update: To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III) [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating safety, tolerability, pulmonary deposition, and pharmacokinetics/pharmacodynamics of inhaled ciprofloxacin in Japanese patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Ciprofloxacin Inhale (ciprofloxacin)

Snippet

Sponsor: Bayer | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED